Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors

NCT05381909 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT05381909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05381909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of Second Mitochondrial-derived Activator of Caspases Mimetic BGB-24714 as Monotherapy and With Combination Therapies in Patients With Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 1
Overall status
Terminated
Start date
July 6, 2022
Completion date
July 25, 2025
Enrollment
157 (actual)
Sites
34

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult